One retrospective study has systemically evaluated the risk of infection in 748 melanoma patients receiving ICIs (CTLA-4, PD-1, and/or PD-L1) [66]: 658 (73.2%) received ipilimumab, 52 (5.7%) received nivolumab, 83 (9.2%) received pembrolizumab, and 105 (11.7%) received a combination therapy. Here, CTLA4 is linked to infection.